New England Journal of Medicine Publishes New Data for Genentech's Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis February 7, 2025 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:War crimes court condemns Trump's sanctions against its staff Back: All Posts Next:Announcement of Embraer Netherlands Finance B.V.'s Pricing of US$650,000,000 of 5.980% Notes Due 2035